References
- O’Brien KL, Wolfson LJ, Watt JP, et al. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 374(9693):893–902.
- Wahl B, O’Brien KL, Greenbaum A, et al. 2018. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 6(7):e744–e57.
- Organization WH. 2019. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – february 2019. Weekly Epidemiological Rec. 94(8):85–104.
- de Oliveira LH, Trumbo SP, Ruiz Matus C, et al. 2016. Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned. Expert Rev Vaccines. 15(10):1295–1304.
- Caceres DC, Ortega-Barria E, Nieto J, et al. 2018. Pneumococcal meningitis trends after pneumococcal conjugate vaccine introduction in Colombia: an interrupted time-series analysis. Hum Vaccin Immunother. 14(5):1230–1233.
- Caceres DC, deAntonio R, Nieto J, et al. Estimated annual impact of pneumococcal conjugate vaccine (PCV) immunization program in Colombia (2011-2018). Value Health Regional Issues. 2019;19:S43.
- Cohen O, Knoll M, O’Brien K, et al.Pneumococcal Conjugate Vaccine (PCV) Product Assessment (2017) [ Accessed 2017Sept29]; Available from: https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf.
- de Oliveira LH, Camacho LA, Coutinho ES, et al., 2016. Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review. PLoS One. 11(12): e0166736.
- Organization WH. Meeting of the Strategic Advisory Group of Experts (SAGE) on immunization, October 2017 – conclusions and recommendations. Weekly Epidemiological Rec. 2017;92:729–748.
- Castaneda-Orjuela C, Alvis-Guzman N, Velandia-Gonzalez M, et al., 2012. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine. 30(11): 1936–1943.
- Marti SG, Colantonio L, Bardach A, et al. 2013. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc. 11(1):21.
- Ordonez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia. Cost Eff Resour Alloc. 2015;13(1):6.
- Castaneda-Orjuela C, De la Hoz-restrepo F. 2018. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country. Vaccine. 36(38):5766–5773.
- Garay OU, Caporale JE, Pichon-Riviere A, et al. [Budgetary impact analysis in health: update with a model using a generic approach]. Rev Peru Med Exp Salud Publica. 2011;28(3):540–547.
- Sullivan SD, Mauskopf JA, Augustovski F, et al. 2014. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 17(1):5–14.
- Deceuninck G, De Serres G, Boulianne N, et al. 2015. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 33(23):2684–2689.
- Tregnaghi MW, Saez-Llorens X, Lopez P, et al. 2014. Efficacy of pneumococcal non typable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial. PLoS Med. 11(6):e1001657.
- Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;4:CD004977.
- Black S, Shinefield H, Fireman B, et al. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 19(3):187–195.
- Pan-American Health Organization (PAHO). PAHO. Pneumococcal Conjugated Vaccine Coverage in Colombia, 2017 (2017) [ Accessed 2020Jul23]; Available from: http://ais.paho.org/imm/IM_JRF_COVERAGE.asp.
- Ministerio de Salud y Protección Social (Colombia). Aseguramiento al Sistema General de Seguridad Social en Salud. Bogotá: MSPS (2014) [ Accessed 2019Nov28]
- ECLAC: Economic Commission for Latin America and the Caribbean. Population database. The 2017 revision. Based on Projections 2015–2030 (2017) [ Accessed 2020Jul23]; Available from: https://www.cepal.org/es/temas/proyecciones-demograficas/estimaciones-proyecciones-poblacion-total-urbana-rural-economicamente-activa.
- Benavides JA, Ovalle OO, Salvador GR, et al. 2012. Population-based surveillance for invasive pneumococcal disease and pneumonia in infants and young children in Bogota, Colombia. Vaccine. 30(40):5886–5892.
- Departamento Administrativo Nacional de Estadística (DANE). Historic Annual IPC, DANE, Colombia (2019) [ Accessed 2020Jul23]; Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc/ipc-historico#variaciones-ipc-base–2008.
- XE Currency Data. Historic exchange rate between US dollar and the Colombian peso (2019) [ Accessed 23 July 2020]; Available from: https://www.xe.com/es/currencytables/.
- Castaneda-Orjuela C, Romero M, Arce P, et al. 2013. Using standardized tools to improve immunization costing data for program planning: the cost of the Colombian Expanded Program on Immunization. Vaccine. 31(Suppl 3):C72–9.
- Pan-American Health Organization (PAHO). PAHO, Expanded Program of Immunization, Vaccine Prices between 2011–2019 (2019) [ Accessed 2019Apr1]; Available from: https://www.paho.org/hq/index.php?option=com_content&view=article&id=1864:paho-revolving-fund&Itemid=4135&lang=en.
- Pan-American Health Organization (PAHO), World Health Organization. Health in the Americas. Colombia (2017) [ Accessed 2020Jul23]; Available from: https://www.paho.org/salud-en-las-americas-2017/?p=2342.
- Ministry of Health. Lineamientos para la gestión y administración del Programa Ampliado de Inmunizaciones (PAI) (2019) [ Accessed 2020Jul23]; Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/lineamientos-gestion-administracion-pai.pdf.
- Ministry of Health. The Ministry of Health starts an initiative for Malaria elimination in Colombia. News bulletin No. 185 (2019) [ Accessed 23 July 2020]; Available from: https://www.minsalud.gov.co/Paginas/Minsalud-lanza-Iniciativa-de-Eliminacion-de-la-Malaria-en-Colombia.aspx.
- Ministry of Health. Combined prevention, an effective response in the fight against HIV/ AIDS. News bulletin No. 180 (2019) [ Accessed 2020Jul23]; Available from: https://www.minsalud.gov.co/Paginas/Prevencion-combinada-respuesta-efectiva-en-lucha-contra-VIHSida.aspx.
- World Bank. World Development Indicators. Colombia (2019) [ Accessed 2019Dec1]; Available from: https://databank.worldbank.org/reports.aspx?source=2&series=SH.XPD.CHEX.GD.ZS&country=COL.
- Ministry of Health. $31.8 billons for health in 2020. News bulletin No. 1 (2020) [ Accessed 2020Jul23]; Available from: https://www.minsalud.gov.co/Paginas/31-8-billones-para-la-salud-en-2020.aspx.
- World Health Organization. Immunization Financing Indicators. Colombia (2020) [ Accessed 2020Jan1]; Available from: https://www.who.int/immunization/programmes_systems/financing/data_indicators/en/.
- O’Riordan M, Fitzpatrick F. The impact of economic recession on infection prevention and control. J Hosp Infect. 2015;89(4):340–345.
- Maltezou HC, Lionis C. The financial crisis and the expected effects on vaccinations in Europe: a literature review. Infect Dis (Lond). 2015;47(7):437–446.
- Gellin B, Landry S. The value of vaccines: our nation’s front line against infectious diseases. Clin Pharmacol Ther. 2010;88(5):580–581.
- Quilici S, Smith R, Signorelli C. Role of vaccination in economic growth. J Mark Access Health Policy. 2015;3:1. 27044. DOI:10.3402/ jmahp.v3.27044
- Borgonovi E, Compagni A. Sustaining universal health coverage: the interaction of social, political, and economic sustainability. Value Health. 2013;16(1 Suppl):S34–8.